牛牛AI助理已提取核心訊息
On February 20, 2024, a significant filing was made with the United States Securities and Exchange Commission (SEC) by New Dimensions Trading Ltd. and Jacob Safier, reporting a collective beneficial ownership of 350,000 shares of T2 Biosystems, Inc. This stake represents 7.1% of the company, based on the total number of shares outstanding as reported in T2 Biosystems' Proxy Statement filed on March 4, 2024. The filing, made under Schedule 13G, indicates that neither New Dimensions Trading Ltd. nor Jacob Safier, who may be deemed to beneficially own the shares due to his role as portfolio manager, have acquired the shares with the intent to change or influence the control of T2 Biosystems. The filing was certified as true and correct by Chana Edelstein, Director of New Dimensions Trading Ltd., and Jacob Safier on March 11, 2024. The joint filing agreement also indicates that any amendments to the Schedule 13G statement will be filed on behalf of both parties.
On February 20, 2024, a significant filing was made with the United States Securities and Exchange Commission (SEC) by New Dimensions Trading Ltd. and Jacob Safier, reporting a collective beneficial ownership of 350,000 shares of T2 Biosystems, Inc. This stake represents 7.1% of the company, based on the total number of shares outstanding as reported in T2 Biosystems' Proxy Statement filed on March 4, 2024. The filing, made under Schedule 13G, indicates that neither New Dimensions Trading Ltd. nor Jacob Safier, who may be deemed to beneficially own the shares due to his role as portfolio manager, have acquired the shares with the intent to change or influence the control of T2 Biosystems. The filing was certified as true and correct by Chana Edelstein, Director of New Dimensions Trading Ltd., and Jacob Safier on March 11, 2024. The joint filing agreement also indicates that any amendments to the Schedule 13G statement will be filed on behalf of both parties.
2024年2月20日，New Dimensions Trading Ltd.和Jacob Safier向美國證券交易委員會（SEC）提交了一份重要文件，報告了T2 Biosystems, Inc.35萬股股份的集體實益所有權。根據T2 Biosystems於2024年3月4日提交的委託書中報告的已發行股票總數，該股份佔該公司的7.1％。這份根據附表13G提交的文件表明，New Dimensions Trading Ltd.和由於擔任投資組合經理而可能被視爲實益擁有這些股份的雅各布·薩菲爾都沒有意圖改變或影響T2 Biosystems的控制權而收購這些股份。2024 年 3 月 11 日，New Dimensions Trading Ltd. 董事查娜·愛德斯坦和雅各布·薩菲爾將該文件認證爲真實無誤。聯合申報協議還規定，對附表13G聲明的任何修正都將代表雙方提交。
2024年2月20日，New Dimensions Trading Ltd.和Jacob Safier向美國證券交易委員會（SEC）提交了一份重要文件，報告了T2 Biosystems, Inc.35萬股股份的集體實益所有權。根據T2 Biosystems於2024年3月4日提交的委託書中報告的已發行股票總數，該股份佔該公司的7.1％。這份根據附表13G提交的文件表明，New Dimensions Trading Ltd.和由於擔任投資組合經理而可能被視爲實益擁有這些股份的雅各布·薩菲爾都沒有意圖改變或影響T2 Biosystems的控制權而收購這些股份。2024 年 3 月 11 日，New Dimensions Trading Ltd. 董事查娜·愛德斯坦和雅各布·薩菲爾將該文件認證爲真實無誤。聯合申報協議還規定，對附表13G聲明的任何修正都將代表雙方提交。
有用
沒用